Developer docs
API playgroundTry for free, no card

Search company profiles

BioHarvest Sciences

Full company profile

uuid0000uto

Namestring
BioHarvest Sciences
Legal namestring
BioHarvest Sciences Inc.
Websiteurl
bioharvest.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

BioHarvest Sciences Inc. (Nasdaq: BHST), founded in 2007 in Israel by Dr. Yochi Hagay and Dr. Zaki Rakib and headquartered in Vancouver, Canada, operates a plant cell biology platform under two integrated business units. The proprietary Botanical Synthesis technology, marketed as Bio-Plant Cellicitation, grows plant cells in industrial bioreactors without cultivating the underlying plant, producing fingerprint-consistent, patentable compositions branded as Biologics+ with dramatically lower land, energy, and time inputs than traditional agriculture. The Direct-to-Consumer Products unit sells the VINIA family of red grape cell nutraceuticals (capsules, hydration drinks, functional coffee, tea, and chews) primarily through the Vinia.com subscription e-commerce platform and Amazon, reaching 85,000-90,000 active users at over 90% subscription mix. The CDMO Services unit, launched in March 2024, offers contract development and manufacturing to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies, charging $2.5-3.0M in non-recurring engineering fees per multi-stage program while retaining ownership stakes and manufacturing royalties on successful compounds. Revenue in FY2025 reached $34.5M (37% YoY growth) with gross margins of 58-60% and Q4 2025 marking the first quarter of positive adjusted EBITDA ($0.5M). The company partners with Tate & Lyle for next-generation sweeteners, SaffronTech for saffron compounds, and a UAE-based fragrance group for rare scent compounds, while expanding into a new 80,000 square foot corporate campus in Yavneh, Israel. Following the April 2026 CEO transition in which co-founder Dr. Zaki Rakib assumed the CEO role, BioHarvest is positioned as a platform-plus-products biotech operating at the intersection of nutraceutical commercialization and contract development services.

Short descriptiontext

BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce nutraceutical and pharmaceutical compounds without traditional agriculture. It sells the VINIA red grape cell brand direct-to-consumers and offers contract development and manufacturing services to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
botanical synthesis platform, plant cell bioprocessing, nutraceutical manufacturing, CDMO services, resveratrol supplements
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Biological Products, (No Disgnostic Substances)2836
Product category
Nutraceuticals & Botanical Ingredients
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Direct-to-Consumer (D2C) Products
TypeSubscription Recurring
Description

BioHarvest generates revenue through proprietary nutraceutical products sold directly to consumers via e-commerce (Vinia.com) and Amazon. The flagship VINIA brand includes capsules, functional beverages (coffee, tea), hydration products, and chews. Revenue is subscription-based with over 90% of purchases being subscription, providing predictable recurring revenue. FY2025 revenues of $34.5 million with 37% year-over-year growth.

bioharvest.com
2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services generating milestone-based revenue through staged development agreements. Partners pay Non-Recurring Engineering (NRE) costs of $2.5M-$3.0M for compound development. BioHarvest retains manufacturing royalties on successful compounds. The division targets pharmaceuticals, nutraceuticals, cosmeceuticals, and nutrition companies seeking novel plant-based compounds.

bioharvest.com
3Manufacturing Royalties
TypeLicensing Royalties
Description

Royalty-driven revenue model from CDMO partnerships where BioHarvest earns manufacturing royalties on future compound production. Retains ownership stakes in developed compositions (e.g., 25% in saffron composition, 20% in fragrance compounds) and receives ongoing royalties from commercial production.

bioharvest.com
4VINIA Inside Ingredient Licensing
TypeLicensing Royalties
Description

Licensing of proprietary VINIA Piceid resveratrol technology to food and beverage manufacturers for incorporation into consumer products. Tate & Lyle partnership represents the flagship example of this ingredient solutions model.

bioharvest.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details2 tiers
1VINIA subscription model with over 90% subscription-based purchases
ModelSubscriptionBilling cadenceMonthly
Notes

Subscription model for VINIA capsules and products through Vinia.com

bioharvest.com
2CDMO Non-Recurring Engineering (NRE) costs ranging from $2.5M to $3.0M per development program
ModelHybridBilling cadenceMulti-year contract
Notes

NRE costs paid by CDMO partner for development; ongoing manufacturing royalties from commercial production (~80% gross margins expected)

bioharvest.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1VINIA
Description

Flagship red grape cell nutraceutical product containing the entire matrix of polyphenols including Piceid Resveratrol. The #1 Resveratrol Polyphenol Brand in the United States with over 85,000 active users.

bioharvest.com
+3 more records
Core offering1 text field

BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce fingerprint-consistent, patentable plant-based compounds without growing the underlying plant. The company runs two business units: a Direct-to-Consumer product unit selling the VINIA line of red grape cell nutraceuticals (capsules, functional beverages, hydration drinks, and chews) primarily through subscriptions, and a Contract Development and Manufacturing Organization (CDMO) services unit that partners with pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies to develop novel plant-based molecules on a milestone and royalty basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 70% increase in arterial dilation after 12 weeks of daily VINIA consumption (clinical trial)
+9 more records
Product overview1 text field

BioHarvest Sciences operates a platform-plus-products architecture centered on its proprietary Botanical Synthesis technology, which grows plant-based compounds without growing the underlying plant. The company serves two business verticals: a Direct-to-Consumer (D2C) Products business offering the VINIA family of nutraceutical products (capsules, hydration drinks, functional beverages, and chews), and a CDMO Services division providing contract development and manufacturing to pharmaceutical, nutraceutical, cosmeceutical, and nutrition partners. The core platform enables the creation of patentable botanical compositions while products like VINIA Blood Flow Hydration, VINIA Daily Chews, and VINIA SuperFood functional beverages extend the technology into consumer markets.

Product and service6 records
1VINIA Red Grape Cell Capsules
CategoryNutraceutical Capsules
Description

Proprietary red grape cell nutraceutical capsules containing the entire matrix of polyphenols including Piceid Resveratrol. Designed to boost nitric oxide production and increase blood flow rate, supporting cardiovascular health, mental alertness, energy, and circulation for health-conscious consumers.

2VINIA Blood Flow Hydration
CategoryFunctional Beverages
Description

First hydration formula powered by VINIA's blood flow technology, combining naturally sourced electrolytes with clinically studied red grape polyphenols to improve arterial dilation and enhance fluid delivery for active consumers.

3VINIA Daily Chews 2X Formula
CategoryNutraceutical Chews
Description

Chewable nutraceutical product with double-strength performance formula featuring VINIA red grape cell extract, designed to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles.

4VINIA Functional Superfood Coffee
CategoryFunctional Beverages
Description

Functional coffee product line featuring VINIA Red Grape Superfood, designed to deliver blood flow benefits through daily coffee consumption.

5VINIA SuperFood Functional Tea
CategoryFunctional Beverages
Description

Functional tea line infused with Piceid Resveratrol targeting the North American functional tea market, offering clinically supported blood flow benefits in a tea format.

6CDMO Services (Biologics+)
CategoryContract Development & Manufacturing
Description

Contract Development and Manufacturing Organization services leveraging the proprietary Botanical Synthesis platform, enabling pharmaceutical, nutraceutical, cosmeceutical, and nutrition industry partners to develop unique, patentable plant-based molecules with development timelines of 18-27 months and NRE costs of $2.5M-$3.0M paid by partner.

Scale indicator34 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

$1.2 million Stage 2 contract for development of rare scent-producing plant compound for global fragrance industry. Multi-stage development program targeting $23 billion premium fragrance market. BioHarvest retains 20% ownership of successfully developed compositions and serves as manufacturing entity under royalty-driven model. Stage 2 project will produce material for commercial trials over six-to-nine months with production readiness targeted for H2 2027.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Strategic CDMO partnership to develop and commercialize saffron-derived botanical compounds using Botanical Synthesis technology. Addresses saffron supply constraints, cost, and environmental impact. Combines BioHarvest's bioreactor methods with Saffron Tech's saffron cultivation expertise. BioHarvest retained 25% ownership in developed saffron composition and earns manufacturing royalties. Stage 1 completed May 2026, advancing to Stage 2 valued at $1.125 million. Targets global saffron market estimated at nearly $500 million annually.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-11
Description

Flagship partnership with global food ingredient leader Tate & Lyle to develop next-generation plant-based sweeteners using BioHarvest's Botanical Synthesis platform. Initial agreement signed December 2024, expanded in May 2026 to include multiple sweetener molecules targeting sugar reduction in food and beverage applications. Reflects strong technical progress and Tate & Lyle's ambition to equip manufacturers with flexible sweetening solutions. Tate & Lyle reported pro forma revenue of £2.12 billion for FY2025 following its acquisition of CP Kelco.

4Nasdaq-listed pharmaceutical company
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-02-26
Description

CDMO contract with a Nasdaq-listed pharmaceutical company with an approved drug. First CDMO project to successfully complete Stage 1 and advance to Stage 2, validating the Botanical Synthesis platform for a variety of molecule types. Demonstrates platform capability for pharmaceutical applications.

bioharvest.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-16
Description

Partnership to supply disruptive cannabis solutions to companies conducting FDA-approved medical research. Provides cannabis compounds produced via Botanical Synthesis platform without growing the cannabis plant, addressing consistency and cleanliness challenges in the industry.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-01
Description

Formal partnership with SpaceTango to explore effects of microgravity on plant cells and potential role of BioHarvest's technology supporting space travel and human settlements in space. Aligned with long-term sustainability vision including space applications.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-12-23
Description

First significant B2B VINIA sale in the US market announced December 2020. Batory Foods serves as a distribution channel for VINIA products to foodservice and ingredient customers.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioHarvest Sciences

Nutraceuticals & Botanical Ingredientsbioharvest.com

BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce nutraceutical and pharmaceutical compounds without traditional agriculture. It sells the VINIA red grape cell brand direct-to-consumers and offers contract development and manufacturing services to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies worldwide.

What BioHarvest Sciences does

BioHarvest Sciences Inc. (Nasdaq: BHST), founded in 2007 in Israel by Dr. Yochi Hagay and Dr. Zaki Rakib and headquartered in Vancouver, Canada, operates a plant cell biology platform under two integrated business units. The proprietary Botanical Synthesis technology, marketed as Bio-Plant Cellicitation, grows plant cells in industrial bioreactors without cultivating the underlying plant, producing fingerprint-consistent, patentable compositions branded as Biologics+ with dramatically lower land, energy, and time inputs than traditional agriculture. The Direct-to-Consumer Products unit sells the VINIA family of red grape cell nutraceuticals (capsules, hydration drinks, functional coffee, tea, and chews) primarily through the Vinia.com subscription e-commerce platform and Amazon, reaching 85,000-90,000 active users at over 90% subscription mix. The CDMO Services unit, launched in March 2024, offers contract development and manufacturing to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies, charging $2.5-3.0M in non-recurring engineering fees per multi-stage program while retaining ownership stakes and manufacturing royalties on successful compounds. Revenue in FY2025 reached $34.5M (37% YoY growth) with gross margins of 58-60% and Q4 2025 marking the first quarter of positive adjusted EBITDA ($0.5M). The company partners with Tate & Lyle for next-generation sweeteners, SaffronTech for saffron compounds, and a UAE-based fragrance group for rare scent compounds, while expanding into a new 80,000 square foot corporate campus in Yavneh, Israel. Following the April 2026 CEO transition in which co-founder Dr. Zaki Rakib assumed the CEO role, BioHarvest is positioned as a platform-plus-products biotech operating at the intersection of nutraceutical commercialization and contract development services.

BioHarvest Sciences firmographics

Firmographics
Name
BioHarvest Sciences
Legal name
BioHarvest Sciences Inc.
Website
https://bioharvest.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce nutraceutical and pharmaceutical compounds without traditional agriculture. It sells the VINIA red grape cell brand direct-to-consumers and offers contract development and manufacturing services to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies worldwide.
Ownership category
akta.pro rank

BioHarvest Sciences industry classification

Industry
Product category
Nutraceuticals & Botanical Ingredients
NAICS
Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Botanical synthesis platform
  • Plant cell bioprocessing
  • Nutraceutical manufacturing
  • CDMO services
  • Resveratrol supplements

Where BioHarvest Sciences is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

BioHarvest Sciences business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Direct-to-Consumer (D2C) Products: BioHarvest generates revenue through proprietary nutraceutical products sold directly to consumers via e-commerce (Vinia.com) and Amazon. The flagship VINIA brand includes capsules, functional beverages (coffee, tea), hydration products, and chews. Revenue is subscription-based with over 90% of purchases being subscription, providing predictable recurring revenue. FY2025 revenues of $34.5 million with 37% year-over-year growth.
  2. CDMO Services: Contract Development and Manufacturing Organization services generating milestone-based revenue through staged development agreements. Partners pay Non-Recurring Engineering (NRE) costs of $2.5M-$3.0M for compound development. BioHarvest retains manufacturing royalties on successful compounds. The division targets pharmaceuticals, nutraceuticals, cosmeceuticals, and nutrition companies seeking novel plant-based compounds.
  3. Manufacturing Royalties: Royalty-driven revenue model from CDMO partnerships where BioHarvest earns manufacturing royalties on future compound production. Retains ownership stakes in developed compositions (e.g., 25% in saffron composition, 20% in fragrance compounds) and receives ongoing royalties from commercial production.
  4. VINIA Inside Ingredient Licensing: Licensing of proprietary VINIA Piceid resveratrol technology to food and beverage manufacturers for incorporation into consumer products. Tate & Lyle partnership represents the flagship example of this ingredient solutions model.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyVINIA subscription model with over 90% subscription-based purchases
HybridMulti-year contractCDMO Non-Recurring Engineering (NRE) costs ranging from $2.5M to $3.0M per development program

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

BioHarvest Sciences product offering

Product offering

Core offering

BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce fingerprint-consistent, patentable plant-based compounds without growing the underlying plant. The company runs two business units: a Direct-to-Consumer product unit selling the VINIA line of red grape cell nutraceuticals (capsules, functional beverages, hydration drinks, and chews) primarily through subscriptions, and a Contract Development and Manufacturing Organization (CDMO) services unit that partners with pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies to develop novel plant-based molecules on a milestone and royalty basis.

Product overview

BioHarvest Sciences operates a platform-plus-products architecture centered on its proprietary Botanical Synthesis technology, which grows plant-based compounds without growing the underlying plant. The company serves two business verticals: a Direct-to-Consumer (D2C) Products business offering the VINIA family of nutraceutical products (capsules, hydration drinks, functional beverages, and chews), and a CDMO Services division providing contract development and manufacturing to pharmaceutical, nutraceutical, cosmeceutical, and nutrition partners. The core platform enables the creation of patentable botanical compositions while products like VINIA Blood Flow Hydration, VINIA Daily Chews, and VINIA SuperFood functional beverages extend the technology into consumer markets.

Differentiator

Problem solved

Functional benefit

Brands

  • VINIA: Flagship red grape cell nutraceutical product containing the entire matrix of polyphenols including Piceid Resveratrol. The #1 Resveratrol Polyphenol Brand in the United States with over 85,000 active users.
  • BIOLOGICS+
  • VINIA Inside
  • CDMO Services

Products and services

  • VINIA Red Grape Cell Capsules Proprietary red grape cell nutraceutical capsules containing the entire matrix of polyphenols including Piceid Resveratrol. Designed to boost nitric oxide production and increase blood flow rate, supporting cardiovascular health, mental alertness, energy, and circulation for health-conscious consumers.
  • VINIA Blood Flow Hydration First hydration formula powered by VINIA's blood flow technology, combining naturally sourced electrolytes with clinically studied red grape polyphenols to improve arterial dilation and enhance fluid delivery for active consumers.
  • VINIA Daily Chews 2X Formula Chewable nutraceutical product with double-strength performance formula featuring VINIA red grape cell extract, designed to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles.
  • VINIA Functional Superfood Coffee Functional coffee product line featuring VINIA Red Grape Superfood, designed to deliver blood flow benefits through daily coffee consumption.
  • VINIA SuperFood Functional Tea Functional tea line infused with Piceid Resveratrol targeting the North American functional tea market, offering clinically supported blood flow benefits in a tea format.
  • CDMO Services (Biologics+) Contract Development and Manufacturing Organization services leveraging the proprietary Botanical Synthesis platform, enabling pharmaceutical, nutraceutical, cosmeceutical, and nutrition industry partners to develop unique, patentable plant-based molecules with development timelines of 18-27 months and NRE costs of $2.5M-$3.0M paid by partner.

Quantifiable outcome

  • 70% increase in arterial dilation after 12 weeks of daily VINIA consumption (clinical trial)
  • +9 more outcomes

Companies that use BioHarvest Sciences

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles4 records

BioHarvest Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioHarvest Sciences partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, core and minor.

  • UAE-based fragrance investment groupmajorStrategic or Co-development Partner · 31 March 2026$1.2 million Stage 2 contract for development of rare scent-producing plant compound for global fragrance industry. Multi-stage development program targeting $23 billion premium fragrance market. BioHarvest retains 20% ownership of successfully developed compositions and serves as manufacturing entity under royalty-driven model. Stage 2 project will produce material for commercial trials over six-to-nine months with production readiness targeted for H2 2027.
  • SaffronTechcoreStrategic or Co-development Partner · 30 October 2025Strategic CDMO partnership to develop and commercialize saffron-derived botanical compounds using Botanical Synthesis technology. Addresses saffron supply constraints, cost, and environmental impact. Combines BioHarvest's bioreactor methods with Saffron Tech's saffron cultivation expertise. BioHarvest retained 25% ownership in developed saffron composition and earns manufacturing royalties. Stage 1 completed May 2026, advancing to Stage 2 valued at $1.125 million. Targets global saffron market estimated at nearly $500 million annually.
  • Tate & Lyle PLCcoreStrategic or Co-development Partner · 11 December 2024Flagship partnership with global food ingredient leader Tate & Lyle to develop next-generation plant-based sweeteners using BioHarvest's Botanical Synthesis platform. Initial agreement signed December 2024, expanded in May 2026 to include multiple sweetener molecules targeting sugar reduction in food and beverage applications. Reflects strong technical progress and Tate & Lyle's ambition to equip manufacturers with flexible sweetening solutions. Tate & Lyle reported pro forma revenue of £2.12 billion for FY2025 following its acquisition of CP Kelco.
  • Nasdaq-listed pharmaceutical companymajorStrategic or Co-development Partner · 26 February 2024CDMO contract with a Nasdaq-listed pharmaceutical company with an approved drug. First CDMO project to successfully complete Stage 1 and advance to Stage 2, validating the Botanical Synthesis platform for a variety of molecule types. Demonstrates platform capability for pharmaceutical applications.
  • Royal Emerald PharmaceuticalsminorStrategic or Co-development Partner · 16 November 2022Partnership to supply disruptive cannabis solutions to companies conducting FDA-approved medical research. Provides cannabis compounds produced via Botanical Synthesis platform without growing the cannabis plant, addressing consistency and cleanliness challenges in the industry.
  • SpaceTangominorStrategic or Co-development Partner · 1 December 2021Formal partnership with SpaceTango to explore effects of microgravity on plant cells and potential role of BioHarvest's technology supporting space travel and human settlements in space. Aligned with long-term sustainability vision including space applications.
  • Batory FoodsminorChannel Partner/ Reseller/ Distributor · 23 December 2020First significant B2B VINIA sale in the US market announced December 2020. Batory Foods serves as a distribution channel for VINIA products to foodservice and ingredient customers.

Scale indicators34 records

Recent moves11 records

Expansion highlights6 records

BioHarvest Sciences competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BioHarvest Sciences social profiles

Digital presence

BioHarvest Sciences compliance and trust

Trust signal

Compliance1 record

BioHarvest Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioHarvest Sciences leadership team

Management profile

Number of profiles

Profiles15 records

BioHarvest Sciences funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioHarvest Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioHarvest Sciences

What does BioHarvest Sciences do?

BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce fingerprint-consistent, patentable plant-based compounds without growing the underlying plant. The company runs two business units: a Direct-to-Consumer product unit selling the VINIA line of red grape cell nutraceuticals (capsules, functional beverages, hydration drinks, and chews) primarily through subscriptions, and a Contract Development and Manufacturing Organization (CDMO) services unit that partners with pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies to develop novel plant-based molecules on a milestone and royalty basis.

Is BioHarvest Sciences a public or private company?

BioHarvest Sciences is a public company. It is classified as public and is currently operating.

When was BioHarvest Sciences founded?

BioHarvest Sciences was founded in 2007. It employs 51 to 100 people.

Where is BioHarvest Sciences based?

BioHarvest Sciences is headquartered in Vancouver, Canada, in the North America region.

How does BioHarvest Sciences make money?

Four revenue lines are on record. Direct-to-Consumer (D2C) Products are the primary driver. The others are CDMO Services, manufacturing Royalties and VINIA Inside Ingredient Licensing.

Does BioHarvest Sciences have an API?

No public API is recorded for BioHarvest Sciences.

What industry is BioHarvest Sciences in?

BioHarvest Sciences's product category is Nutraceuticals & Botanical Ingredients. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ProactiveinvestorsBioHarvest Sciences posts US$7.9M Q3 revenue as fragrance supply deal sets up 2027 growthBioHarvest Sciences reported Q3 2026 revenue of $7.9 million, down from $9.1 million a year earlier, and posted a net loss of $3.3 million. The company said its first fragrance supply agreement is estimated to generate $20-30 million in revenue in 2027-2028, with limited production possible as early as Q1 2027.Investing.comEarnings call transcript: BioHarvest Sciences posts lower Q3 2026 revenueBioHarvest Sciences reported Q3 2026 revenue of $7.9 million, down 13.2% year-over-year, and a net loss of $3.3 million. The company raised its full-year 2026 revenue outlook to $32–33.5 million and expects VINIA revenue to grow in Q1 2027.BenzingaBioHarvest Sciences Q3 2026 Earnings Call Transcript - BioHarvest Sciences (NASDAQ:BHST)BioHarvest Sciences reported Q3 2026 revenue of $7.9 million, down from $9.1 million, and a net loss of $3.3 million. The company signed an exclusive CDMO agreement for a rare fragrance ingredient, expected to generate $20-30 million in revenue over 2027-2028. It updated its 2026 outlook to $32-33.5 million revenue and an adjusted EBITDA loss of $5.5-7.5 million.TradingViewBioHarvest Sciences Q3 2026 Earnings Call Is LiveBioHarvest Sciences' Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary can move markets as much as the earnings release itself.Stock TitanBioHarvest Sciences Q3 2026 results: revenue falls to $7.9MBioHarvest Sciences reported Q3 2026 revenue of $7.9 million, down from $8.8 million in Q2 2026, and an operating loss of $3 million. The company revised its full-year 2026 revenue guidance to $32-33.5 million and plans to consolidate development sites in 2027.Defense WorldBioHarvest Sciences (BHST) Projected to Announce Quarterly Earnings on ThursdayBioHarvest Sciences is projected to announce Q3 2026 earnings on Thursday, November 12th, with analysts expecting a loss of $0.16 per share and revenue of $9.31 million. The company's last quarterly report missed estimates with a loss of $0.17 per share and revenue of $8.84 million. Analysts have a consensus 'Hold' rating with a price target of $6.50.Defense WorldBioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head ContrastBioHarvest Sciences and Haleon are compared on profitability, valuation, risk, and analyst ratings. Haleon has higher revenue and earnings, but BioHarvest Sciences trades at a lower P/E and has a higher potential upside. Haleon beats BioHarvest Sciences on 11 of 13 factors.NewsfileBioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026BioHarvest Sciences will report its third quarter 2026 financial results on November 12, 2026, before market opening, and will host a conference call at 8:00 AM Eastern Time. The company will discuss the results and an update on business operations, including progress on its strategic transformation.Seeking AlphaBioHarvest Sciences sets share repurchase plan (BHST:NASDAQ)BioHarvest Sciences' board authorized a share repurchase program under a normal course issuer bid, allowing repurchase of up to 5% of outstanding common shares, or 1,133,392 shares. The NCIB is expected to begin within five days and remain in effect for up to 12 months.